A Powerful Rare Cell
Enrichment Platform

  • Antigen-independent circulating tumor cell (CTC) capture
  • Use any downstream analysis
  • Visualize and quantify CTC biomarkers

ApoStream™ CTC Analysis Technology and Biomarker Services—from Precision for Medicine

Circulating Tumor Cells in Oncology

Circulating tumor cells (CTCs) are cancer cells that are shed into the vasculature from a primary tumor or its metastases and circulate in the peripheral blood. While metastases are directly responsible for the majority of cancer deaths, CTCs may constitute the seeds for subsequent metastasis. Indeed, many studies have shown that the presence of CTCs is of prognostic significance for many different solid tumors.

ApoStream isolates and enriches CTCs, facilitating any type of downstream analysis such as multiplex quantitative immunofluorescence (IF) or FISH/ISH. ApoStream can also be used to collect other rare cell types such as stem cells, progenitor and differentiated immune cells, including CAR T cells and other difficult to identify immune cell populations for immuno-oncology applications.

Circulating Tumor Cells in Oncology

Circulating tumor cells (CTCs) are cancer cells that are shed into the vasculature from a primary tumor or its metastases and circulate in the peripheral blood. While metastases are directly responsible for the majority of cancer deaths, CTCs may constitute the seeds for subsequent metastasis. Indeed, many studies have shown that the presence of CTCs is of prognostic significance for many different solid tumors.

ApoStream isolates and enriches CTCs, facilitating any type of downstream analysis such as multiplex quantitative immunofluorescence (IF) or FISH/ISH. ApoStream can also be used to collect other rare cell types such as stem cells, progenitor and differentiated immune cells, including CAR T cells and other difficult to identify immune cell populations for immuno-oncology applications.

ApoStream Technology Offers a Unique Combination of Impressive Capabilities

Multiplex CTC Panels

Multiplex CTC panels from enriched Ovarian Cancer and TNBC patient samples showing Epithelial (EPI), Mesenchymal (EMT) and other markers.

Capture a high quantity of CTCs from many types of cancer including epithelial and mesenchymal subsets

With antibody-independent capture, various cancer types can be evaluated, including those that are challenging when using antibody-dependent capture techniques.

NSCLC Patient Representative of Stained Images

Magnification of MIF characterization of NSCLC CTCs.

Universal enrichment of many
rare cell subsets

ApoStream technology allows for capture and enrichment of rare cell subsets, enabling downstream applications.

Cancer Patient CTCs Analyzed by FISH

Fluorescence in-situ hybridisation (FISH) images were acquired with Metasystems platform and analyzed by a certified Cytotechnologist.

High recovery allows for any type of downstream analysis

Because of the high percentage of CTCs captured, ApoStream facilitates multiple downstream analyses, including molecular characterization, protein and gene expression analysis, NGS, pharmacodynamic studies, and multiplex imaging.

CTC Characterization

MIF based characterization of CTCs.

Automated Gating of Quantitative Data

Scatter plot showing quantitative data of marker expression on CTCs.

Quantitative image analysis of biomarkers in multiple CTC phenotypes

ApoStream becomes an extremely powerful biomarker platform when coupled with multiplex IF. This allows for multiplex visualization of several biomarkers in individual CTCs.

ApoStream Enables Molecular and Biological
Investigation of CTCs

In this workflow, we first capture and enrich rare CTCs using our proprietary ApoStream technology. We then stain and image these isolated CTCs using multiplex IF to detect both epithelial and mesenchymal CTC subtypes. Using multiplex IF on proteins within isolated single cells, we are able to generate data on interactions of proteins of interest within a single cell.

Precision is the only CRO experienced in using the Vectra® Polaris™ system on isolated cells.

Selected Publications

Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system.

Balasubramanian P, Kinders RJ, Kummar S, et al. Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system. PLoS ONE. 2017;12(4):e0175414. doi:10.1371/journal.pone.0175414

ApoStream®, a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood.

Gupta V, Jafferji I, Garza M, et al. Biomicrofluidics. 2012;6(2):24133. doi:10.1063/1.4731647

Precision for Medicine is committed to optimizing the full potential of its ApoStream technology platform’s capabilities.

While our primary focus is on providing customized biomarker solutions to biopharma for accelerated drug development, we are also seeking partners interested in commercialization of the ApoStream technology for various industrial applications including infectious disease, CAR T-cell or engineered cell enrichment, purification of viable cell preps, stem cells and fetal cells, etc. The company is open to corporate partnerships that will help continue the commercialization of our proprietary technology so that it will ultimately benefit patient care.

Technology Partnering Inquiry